Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?
Author:
Affiliation:
1. Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
2. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
Funder
Lymphoma Research Foundation
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14656566.2019.1582643
Reference12 articles.
1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
3. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
4. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
5. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise;Blood and Lymphatic Cancer: Targets and Therapy;2023-03
2. An overview of chemotoxicity and radiation toxicity in cancer therapy;Advances in Cancer Research;2022
3. CAR-T in B-Cell Lymphomas: The Past, Present, and Future;Clinical Lymphoma Myeloma and Leukemia;2021-10
4. Role of antibody-based therapy in indolent non-Hodgkin's lymphoma;Leukemia Research Reports;2021
5. Perspectives on chemotherapy for the management of double-hit lymphoma;Expert Opinion on Pharmacotherapy;2020-02-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3